WO2004101607A3 - Comparative ligand mapping from mhc class i positive cells - Google Patents

Comparative ligand mapping from mhc class i positive cells Download PDF

Info

Publication number
WO2004101607A3
WO2004101607A3 PCT/US2004/014932 US2004014932W WO2004101607A3 WO 2004101607 A3 WO2004101607 A3 WO 2004101607A3 US 2004014932 W US2004014932 W US 2004014932W WO 2004101607 A3 WO2004101607 A3 WO 2004101607A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
methodology
identification
positive cells
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/014932
Other languages
French (fr)
Other versions
WO2004101607A2 (en
Inventor
William H Hildebrand
Heather D Hickman-Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP04752061A priority Critical patent/EP1625151A2/en
Publication of WO2004101607A2 publication Critical patent/WO2004101607A2/en
Publication of WO2004101607A3 publication Critical patent/WO2004101607A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates generally to a methodology for the isolation, purification and identification of peptide ligands presented by MHC positive cells. In particular, the methodology of the present invention relates to the isolation, purification and identification of these peptide ligands from soluble class I and class II MHC molecules which may be from uninfected, infected, or tumorigenic cells. The methodology of the present invention broadly allows for these peptide ligands and their cognate source proteins thereof to be identified and used as markers for infected versus uninfected cells and/or tumorigenic versus nontumorigenic cells with said identification being useful for marking or targeting a cell for therapeutic treatment or priming the immune response against infected cells.
PCT/US2004/014932 2003-05-13 2004-05-13 Comparative ligand mapping from mhc class i positive cells Ceased WO2004101607A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04752061A EP1625151A2 (en) 2003-05-13 2004-05-13 Comparative ligand mapping from mhc class i positive cells

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US46999503P 2003-05-13 2003-05-13
US60/469,995 2003-05-13
US51813203P 2003-11-07 2003-11-07
US60/518,132 2003-11-07

Publications (2)

Publication Number Publication Date
WO2004101607A2 WO2004101607A2 (en) 2004-11-25
WO2004101607A3 true WO2004101607A3 (en) 2005-08-11

Family

ID=33457169

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/014932 Ceased WO2004101607A2 (en) 2003-05-13 2004-05-13 Comparative ligand mapping from mhc class i positive cells

Country Status (2)

Country Link
EP (1) EP1625151A2 (en)
WO (1) WO2004101607A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090062512A1 (en) * 2000-10-10 2009-03-05 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
WO2007030451A2 (en) * 2005-09-07 2007-03-15 Receptor Logic, Ltd. Antibodies as t cell receptor mimics, methods of production and uses thereof
EP2740484A1 (en) * 2012-12-05 2014-06-11 Lipotec, S.A. Compounds useful in the treatment and/or care of the skin, hair and/or muccous membranes and their cosmetic or pharmaceutical compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002086122A2 (en) * 2001-03-14 2002-10-31 Hybrigenics Protein-protein interactions in adipocytes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002086122A2 (en) * 2001-03-14 2002-10-31 Hybrigenics Protein-protein interactions in adipocytes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EPO Proteins [online] 27 March 2003 (2003-03-27), "Sequence 1267 from Patent WO02086122.", XP002314962, retrieved from EBI accession no. EPOP:AX678488 Database accession no. AX678488 *
RAMMENSEE HANS-GEORG ET AL: "SYFPEITHI: Database for MHC ligands and peptide motifs", IMMUNOGENETICS, SPRINGER VERLAG, BERLIN, DE, vol. 50, no. 3-4, November 1999 (1999-11-01), pages 213 - 219, XP002183663, ISSN: 0093-7711 *
SATHIAMURTHY M ET AL: "Population of the HLA ligand database.", TISSUE ANTIGENS, vol. 61, no. 1, January 2003 (2003-01-01), pages 12 - 19, XP002314961, ISSN: 0001-2815 *

Also Published As

Publication number Publication date
WO2004101607A2 (en) 2004-11-25
EP1625151A2 (en) 2006-02-15

Similar Documents

Publication Publication Date Title
WO2002030964A3 (en) Comparative ligand mapping from mhc positive cells
WO2004060308A3 (en) Thiosemicarbazones as anti-virals and immunopotentiators
DE602006019629D1 (en) CELL-STRAINING VIRAL VACCINES WITH LOW QUANTITIES OF REST-CELL DNA
WO2009147248A3 (en) Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
WO2004080403A3 (en) Influenza virus vaccine
WO2004024757A3 (en) Modified pna molecules
WO2008017826A3 (en) Immunogenic proteins of burkholderia pseudomallei and uses thereof
EA201001212A1 (en) TREATMENT OF MICROBIAL INFECTIONS
DE602005008996D1 (en) RADIOFLUORATED PEPTIDES
ATE458746T1 (en) MELPHALAN DERIVATIVES AND THEIR USE AS ANTI-CANCER CHEMOTHERAPEUTICS
WO2010041241A3 (en) Hiv-1 integrase derived stimulatory peptides interfering with integrase - rev protein binding
WO2006062402A3 (en) Heat shock proteins (hsp) and supraventricular arrhythmia
WO2009037183A3 (en) Cosmetic and/or pharmaceutical preparation containing nucleic acid for the induction of antimicrobial peptides in epithelia
WO2007019865A3 (en) Therapy with cd4 binding peptides and radiation
CL2008001719A1 (en) Compounds derived from [1,10] -phenanthroline; preparation procedure; pharmaceutical composition; and use in the treatment of neurodegenerative or hematological diseases.
ATE380557T1 (en) E. COLI VACCINE FOR THE PROTECTION OF POULTRY AGAINST COLIBACILOSIS
WO2005023849A3 (en) Antigenic peptides of rabies virus and uses thereof
WO2004101607A3 (en) Comparative ligand mapping from mhc class i positive cells
WO2006137938A3 (en) Antibody fragments for protection from pathogen infection and methods of use thereof
WO2007053644A3 (en) Comparative ligand mapping from mhc class i positive cells
WO2009077744A3 (en) Vaccines for brucellosis
WO2007076091A3 (en) Treatment of viral infections using a tissue factor inhibitor
WO2010046778A3 (en) Novel shigella frotein antigens and methods
DK1537204T3 (en) Granzym B as HSP70 / HSP70 peptide-dependent triggers of programmed cell death in tumor cells
WO2008045017A3 (en) Sars and ebola inhibitors and use thereof, and methods for their discovery

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004752061

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004752061

Country of ref document: EP